文献速递泌尿男性生殖肿瘤

选择性盆腔淋巴结放疗与不良风险前列腺癌患者死亡风险:一项随机化后分析

Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis.
PubMed 文献 · J Clin Oncol · 2024-05-01

2005至2015年,350例局部不良风险前列腺癌患者随机接受雄激素剥夺治疗(ADT)联合放疗加多西他赛或ADT联合放疗,盆腔淋巴结照射由医生决定。中位随访10.20年,88例(25.14%)接受全盆腔放疗(WPRT);65岁以下男性中WPRT与较低的全因死亡率(AHR 0.33,95%CI 0.11-0.97,P=0.04)相关,65岁及以上男性无此关联。

要点

  • 350例不良风险前列腺癌患者随机分组,88例(25.14%)接受全盆腔放疗(WPRT)。
  • 65岁以下男性WPRT与较低全因死亡风险相关(AHR 0.33,95%CI 0.11-0.97,P=0.04)。
  • 65岁以下男性WPRT与前列腺癌特异性死亡风险无显著关联(AHR 0.17,95%CI 0.02-1.35,P=0.09)。

核心结论

  • WPRT可能降低年轻不良风险前列腺癌患者的死亡风险。

研究设计与样本

  • 2005至2015年,350例局部不良风险前列腺癌男性随机接受ADT联合放疗加多西他赛或ADT联合放疗,盆腔淋巴结治疗由主治医生决定。
  • 采用多变量Cox回归和Fine-Gray回归分析评估放疗体积与全因死亡率(ACM)及前列腺癌特异性死亡率(PCSM)的关联,并纳入年龄(以65岁二分)与放疗体积的交互项。

主要发现

  • 中位随访10.20年(IQR 7.96-11.41),89例(25.43%)死亡,其中42例(47.19%)死于前列腺癌。
  • 350例随机分组患者中88例(25.14%)接受WPRT。
  • 65岁以下男性中,WPRT与较低的全因死亡风险相关(校正风险比[AHR] 0.33,95%CI 0.11-0.97,P=0.04)。
  • 65岁以下男性中,WPRT与前列腺癌特异性死亡风险无显著关联(AHR 0.17,95%CI 0.02-1.35,P=0.09)。
  • 65岁及以上男性中未观察到上述关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 盆腔淋巴结治疗由主治医生决定,非随机分配。
  • 原文结论指出WPRT具有降低死亡风险的潜力,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although a contemporary randomized clinical trial has led to the use of whole-pelvic radiation therapy (WPRT), long-term data evaluating a potential reduction in mortality are lacking and are addressed in the current study. MATERIALS AND METHODS: From 2005 to 2015, 350 men with localized, unfavorable-risk prostate cancer (PC) were randomly assigned to receive androgen deprivation therapy (ADT) and RT plus docetaxel versus ADT and RT. Treatment of the pelvic lymph nodes was at the discretion of the treating physician. Multivariable Cox and Fine and Grays regression analyses were performed to assess whether a significant association existed between radiation treatment volume and all-cause mortality (ACM) and PC-specific mortality (PCSM), respectively, adjusting for known PC prognostic factors and comorbidity. An interaction term between age (categorized by dichotomization at 65 years to enable clinical interpretation and applicability of the results and which approximates the median (66 years [IQR, 61-70]) and radiation treatment volume was included in the analysis. RESULTS: After a median follow-up of 10.20 years (IQR, 7.96-11.41), 89 men died (25.43%); of these, 42 died of PC (47.19%). Of the 350 randomly assigned patients, 88 (25.14%) received WPRT. In men younger than 65 years, WPRT was associated with a significantly lower ACM risk (adjusted hazard ratio [AHR], 0.33 [95% CI, 0.11 to 0.97]; P = .04) and lower PCSM risk (AHR, 0.17 [95% CI, 0.02 to 1.35]; P = .09) after adjusting for covariates, whereas this was not the case for men 65 years or older. CONCLUSION: WPRT has the potential to reduce mortality in younger men with unfavorable-risk PC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sayan M, Chen MH, Loffredo M, et al. Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis. J Clin Oncol. 2024. PMID: 38691823. doi:10.1200/JCO.23.02394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。